BIOGEN for BIOGEN
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Discussions regarding Medicaid 340B drug discount program
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| STEPHANIE A. DYSON | — |
| JOHN RAYMOND GIBSON | — |
| MICHELLE MATHY | — |
Pharmacy PHA
Discussions regarding pharmaceutical issues related to supply chain Kingdom of Saudi Arabia issue related to pharmaceuticals H.R.3, Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2019 S.2543, Prescription Drug Pricing Reduction Act of 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| STEPHANIE A. DYSON | — |
| JOHN RAYMOND GIBSON | — |
| MICHELLE MATHY | — |
Health Issues HCR
Discussions regarding rare diseases, Alzheimer's policy, drug pricing, PET scan coverage and reimbursement, and dementia care H.R.3772 - Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis study Discussions regarding Part B home infusion during Covid-19 crisis H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 H.R.6201 - Families First Coronavirus Response Act H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| STEPHANIE A. DYSON | — |
| JOHN RAYMOND GIBSON | — |
| MICHELLE MATHY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.